Acute myeloid leukemia: Focus on novel therapeutic strategies

Clinical Medicine Insights: Oncology

Volumn 6, Issue , 2012, Pages 205-217

  Lin, Tara L ^a   Yair Levy, M ^b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute myeloid leukemia; Cancer stem cells; Clofarabine; FLT3; Gemtuzumab ozogamicin

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTILEUKEMIC AGENT; AZACITIDINE; CELATOR; CLOFARABINE; CPX 351; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; ELACYTARABINE; ETOPOSIDE; FLAVOPIRIDOL; FLUCYTOSINE DEOXYRIBOSIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; LENALIDOMIDE; LOMUSTINE; MITOXANTRONE; PANOBINOSTAT; PLERIXAFOR; QUIZARTINIB; ROMIDEPSIN; SAPACITABINE; TIGECYCLINE; TIOGUANINE; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL RENEWAL; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPIGENETICS; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; HUMAN; INFECTION; LEUKEMIA RELAPSE; LIVER TOXICITY; LOW DRUG DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REFRACTORY PERIOD; REVIEW; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; VEIN OCCLUSION; VOMITING;

EID: 84863911468     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S7244     Document Type: Review

References (85)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. Jul-Aug 2011;61(4):212-36.
2. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. Feb 2011;29(5):495-503.
3. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. Dec 1981;58(6): 1203-12.
4. Yates JW, Wallace HJ, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. Nov-Dec 1973;57(4):485-8.
5. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. Oct 1994;331(14):896-903.
6. Farag SS, Archer KJ, Mrózek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. Jul 2006;108(1): 63-73.
7. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. Oct 1998;92(7):2322-33.
8. Slovak M, Kopecky K, Cassileth P, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. Dec 2000;96(13):4075-83.
9. Byrd J, Mrózek K, Dodge R, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. Dec 2002; 100(13):4325-36.
10. Members NAMLP. NCCN Practice Guidelines in Oncology v.2.2010. Acute Myeloid Leukemia. 2010; http://www.nccn.org/professionals/physician_ gls/PDF/aml.pdf. Accessed Jul 5, 2010.
11. Care RS, Valk PJ, Goodeve AC, et al. Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias. Br J Haematol. Jun 2003;121(5):775-7.
12. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. Aug 2006;24(24): 3904-11.
13. Bienz M, Ludwig M, Leibundgut E, et al. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res. Feb 2005; 11(4):1416-24.
14. Mrózek K, Marcucci G, Paschka P, Whitman S, Bloomfield C. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. Jan 2007;109(2):431-48.
15. Schlenk R, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. May 2008;358(18):1909-18.
16. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. Jan 2010;115(3): 453-474.
17. Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. Jan 2005; 352(3):254-66.
18. Fröhling S, Schlenk R, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. Dec 2002;100(13):4372-80.
19. Fröhling S, Schlenk R, Stolze I, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. Feb 2004;22(4): 624-33.
20. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. Sep 2009;361(13):1249-59.
21. Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol. Feb 2010;28(5):808-14.
22. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. Sep 2009;361(13):1235-48.
23. http://www.clinicaltrials.gov. Accessed Mar 1, 2012.
24. Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. Leuk Res. Sep 2010;34(9): 1214-23.
25. Cortes J, Feldman E, Goldberg S, et al. CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in #65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report. Blood ASH Annual Meeting Abstracts. 2011;118:254.
26. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. Feb 2011;29(4): 369-77.
27. Burnett A, Hills R, Hunter A, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of UK NCRI AML16 randomized trial. Blood ASH Annual Meeting Abstracts. 2011; 118:582.
28. Castaigne S, Pautas C, Terre C, Raffoux E, Bordessoule D. Fractionated Doses of Gemtuzumab Ozogamicin (GO) Combined to Standard Chemotherapy (CT) Improve Event-Free and Overall Survival in Newly-Diagnosed De Novo AML Patients Aged 50-70 Years Old: A Prospective Randomized Phase 3 Trial From the Acute Leukemia French Association (ALFA). Blood ASH Annual Meeting Abstracts. 2011;118:6.
29. Delauney J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamicin to chemotherapy improves event-free survival but not overall survival of AML patients wtih intermediate cytogenetics not eligible for allogeneic transplantation. Resuilts of the GOELAMS AML 2006 IR study. Blood ASH Annual Meeting Abstracts. 2011;118:615.
30. Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. Aug 2011;118(6):1472-80.
31. Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. Dec 2005;11(23):8403-12.
32. Karp JE, Blackford A, Smith BD, et al. Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia. Leuk Res. Jul 2010; 34(7):877-82.
33. Garcia-Manero G, Tambaro F, Bekele N, Yang H. Final report of a phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Blood ASH Annual Meeting Abstracts. 2011;118:763.
34. Menzin J, Lang K, Earle CC, Kerney D, Mallick R. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. Jul 2002;162(14):1597-603.
35. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. May 2006;107(9):3481-5.
36. Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. Nov 2011;29(33):4417-23.
37. Schiffer CA. "I am older, not elderly, " said the patient with acute myeloid leukemia. J Clin Oncol. Feb 2010;28(4):521-3.
38. Fenaux P, Mufti GJ, Hellström-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. Feb 2010;28(4):562-9.
39. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol. Feb 2010;28(4):556-61.
40. Ravandi F, Issa JP, Garcia-Manero G, et al. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. Dec 2009;115(24):5746-51.
41. Blum W, Klisovic RB, Becker H, et al. Dose escalation of lenalidomide in relapsed or refractory acute leukemias. J Clin Oncol. Nov 2010;28(33): 4919-25.
42. Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood. Jul 2011;118(3):523-8.
43. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol. Feb 2010;28(4): 549-55.
44. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol. May 2010;28(14): 2389-95.
45. Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. Jul 2006;108(1):45-51.
46. Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. Sep 2008;112(5):1638-45.
47. Martin MG, Uy GL, Procknow E, et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transplant. Jul 2009;44(1):13-7.
48. Magenau J, Tobai H, Pawarode A, et al. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies. Blood. Oct 2011; 118(15):4258-64.
49. Andersson BS, Valdez BC, de Lima M, et al. Clofarabine-fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. Jun 2011;17(6):893-900.
50. Buchholz S, Dammann E, Stadler M, et al. Cytoreductive treatment with clofarabine/ ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol. Jan 2012;88(1):52-60.
51. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. Feb 1994; 367(6464):645-8.
52. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. Jul 1997;3(7):730-7.
53. Büchner T, Krug U, Berdel WE, et al. Maintenance for acute myeloid leukemia revisited. Curr Treat Options Oncol. Aug 2007;8(4):296-304.
54. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood. Apr 1992;79(8):1924-30.
55. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. Sep 2001;98(5):1302-11.
56. Büchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. Dec 2003;21(24):4496-504.
57. Buyse M, Squifflet P, Lange BJ, et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood. Jun 2011;117(26):7007-13.
58. Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol. Oct 2008;26(30):4934-9.
59. Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res. May 2008;14(10): 3077-82.
60. Chowdhury S, Seropian S, Marks PW. Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol. Sep 2009;84(9):599-600.
61. Graef T, Kuendgen A, Fenk R, Zohren F, Haas R, Kobbe G. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine. Leuk Res. Feb 2007;31(2):257-9.
62. Platzbecker U, Wermke M, Radke J, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. Sep 2011.
63. Wei A, Tan P, Catalano J, Walker P. Azacitidine in combination with the mTOR inhibitor everolimus in relapsed and refractory AML. Blood ASH Annual Meeting Abstracts. 2011;118:2599.
64. Kantarjian H, Gandhi V, Cortes J, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. Oct 2003;102(7):2379-86.
65. Faderl S, Gandhi V, O'Brien S, et al. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. Feb 2005;105(3):940-7.
66. Faderl S, Wetzler M, Rizzieri D, Schiller G, Jagasia M. Clofarabine plus cytarabine compared to cytarabine alone in older patients with relapsed or refractory (R/R) acute myelogenous leukemia (AML): Results from the phase III CLASSIC 1 trial. J Clin Oncol. 2011;29(Suppl);Abstr 6503.
67. Fathi AT, Chabner BA. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations. Oncologist. 2011;16(8):1162-74.
68. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. Dec 2010;116(24):5089-102.
69. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. Sep 2001;98(6): 1752-9.
70. Vardiman J, Thiele J, Arber D, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. Jul 2009;114(5):937-51.
71. Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. Mar 2011;117(12):3294-301.
72. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. Mar 2005; 23(9):1969-78.
73. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. Nov 2004;432(7015):324-31.
74. Taipale J, Beachy P. The Hedgehog and Wnt signalling pathways in cancer. Nature. May 2001;411(6835):349-54.
75. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature. Apr 2009;458(7239):776-9.
76. Lin TL, Wang QH, Brown P, et al. Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926. PLoS One. 2010;5(12):e15262.
77. Peacock CD, Wang Q, Gesell GS, et al. Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc Natl Acad Sci U S A. Mar 2007;104(10):4048-53.
78. Dierks C, Grbic J, Zirlik K, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nature Medicine. 2007;13(8): 944-51.
79. Singh R, Kim J, Davuluri Y, et al. Hedgehog signaling pathway is activated in diffuse large B-cell lymphoma and contributes to tumor cell survival and proliferation. Leukemia. Mar 2010.
80. Jamieson C, Cortes JE, Oehler V, et al. Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies. Blood. 2011;118:424.
81. Amadori S, Stasi R, Martelli AM, et al. Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol. Jan 2012;156(2):205-12.
82. Uy GL, Rettig MP, Motabi IH, et al. A phase I/II study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood. Feb 2012.
83. Skrtić M, Sriskanthadevan S, Jhas B, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell. Nov 2011;20(5):674-88.
84. Bornhäuser M, Illmer T, Schaich M, et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood. Mar 2007; 109(5):2264-5; Author reply 2265.
85. DeZern AE, Sung A, Kim S, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. Sep 2011;17(9):1404-9.